Research Compendium/Ipamorelin
Growth Hormone AxisResearch OnlyNot For Human Consumption

Ipamorelin

GHRP-1 analogue · NNC 26-0161

Selective GHRP with minimal cortisol and prolactin stimulation - the cleanest GH secretagogue in its class.

MECHANISM OF ACTION

Ipamorelin is a pentapeptide GHS-R1a agonist that stimulates pulsatile GH release from pituitary somatotrophs. Unlike GHRP-2 and GHRP-6, it produces minimal cortisol, prolactin, or ACTH stimulation. Preferred GHRP in combination with CJC-1295: CJC-1295 elevates baseline GHRH tone while ipamorelin triggers physiologically-timed GH pulses - synergistic amplification.

RESEARCH APPLICATIONS

  • Selective GH pulse stimulation
  • Body composition - lean/fat ratio studies
  • Sleep quality and nocturnal GH pulse research
  • Combination GHRH/GHRP synergy modelling
  • Bone mineral density (preclinical)

RESEARCH HIGHLIGHTS

Selectivity vs. Earlier GHRPs

1998

Head-to-head in swine models: ipamorelin produced equivalent GH release to GHRP-6 with significantly lower ACTH and cortisol - superior chronic safety profile.

Ref: Raun et al., Eur J Endocrinol

BMD Preservation

2000

12-week ipamorelin in ovariectomised rats showed statistically significant BMD preservation vs. control via IGF-1-mediated osteoblast activity.

Ref: Svensson et al., Growth Horm IGF Res

RESEARCH PROTOCOL NOTES

Research doses100–300 mcg per administration
TimingPre-sleep to maximise nocturnal GH pulse amplitude
Available formatsVial (5–10mg), Pen, self-mix kits (with CJC-1295)

Chemical Identity

Molecular FormulaC38H49N9O5
Molecular Weight711.9 g/mol
CAS Number170851-70-4
Half-Life (t½)~2 hours
SolubilitySoluble in bacteriostatic water

Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH2

Storage & Stability

Lyophilised: -20°C or 2–8°C. Reconstituted: 2–8°C, 28 days. More stable in solution than CJC-1295.

Regulatory Status

No regulatory approval. WADA prohibited (S2). SAHPRA: unscheduled research compound.

Back to Research CompendiumView Research Compounds →